Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers.

about

Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers.

Item

http://www.wikidata.org/entity/Q47554287

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Pharmacokinetic Interactions B ...... t Drugs in Healthy Volunteers.

@en

Pharmacokinetic Interactions B ...... t Drugs in Healthy Volunteers.

@nl

type

Item

label

Pharmacokinetic Interactions B ...... t Drugs in Healthy Volunteers.

@en

Pharmacokinetic Interactions B ...... t Drugs in Healthy Volunteers.

@nl

prefLabel

Pharmacokinetic Interactions B ...... t Drugs in Healthy Volunteers.

@en

Pharmacokinetic Interactions B ...... t Drugs in Healthy Volunteers.

@nl

P1476

Pharmacokinetic Interactions B ...... t Drugs in Healthy Volunteers.

@en

P2093

Christine M Fandozzi

http://www.w3.org/2001/XMLSchema#string

Deborah Panebianco

http://www.w3.org/2001/XMLSchema#string

Dennis Wolford

http://www.w3.org/2001/XMLSchema#string

Hwa-Ping Feng

http://www.w3.org/2001/XMLSchema#string

Jennifer Talaty

http://www.w3.org/2001/XMLSchema#string

Joan R Butterton

http://www.w3.org/2001/XMLSchema#string

Luzelena Caro

http://www.w3.org/2001/XMLSchema#string

Marian Iwamoto

http://www.w3.org/2001/XMLSchema#string

Wendy W Yeh

http://www.w3.org/2001/XMLSchema#string

Zifang Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre

Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.

Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies.

Treatment of hepatitis C after liver transplantation.

Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?

effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.

P31

scholarly article

P356

10.1002/JCPH.1052

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29329497

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression